Autor segons l'article: Maria Mostaza, Jose; Suarez, Carmen; Maria Cepeda, Jose; Manzano, Luis; Sanchez, Demetrio
Departament: Medicina i Cirurgia
Autor/s de la URV: Auguet Quintillà, Maria Teresa
Paraules clau: Warfarin Vitamin k antagonists (vkas) Thromboembolism Stroke prevention Risk stratification schemes Population Nonvalvular atrial fibrillation (nvaf) Mental status questionnaire Management Elderly-patients Direct-acting oral anticoagulants (doacs) Direct oral anticoagulants Bleeding risk Antithrombotic treatment
Resum: Background This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting. Methods A multicenter, cross-sectional study was conducted in NVAF patients who attended internal medicine departments for either a routine visit (outpatients) or hospitalization (inpatients). Results A total of 961 patients were evaluated. Their antithrombotic management included: no treatment (4.7%), vitamin K antagonists (VKAs) (59.6%), direct oral anticoagulants (DOACs) (21.6%), antiplatelets (6.6%), and antiplatelets plus anticoagulants (7.5%). Permanent NVAF and congestive heart failure were associated with preferential use of oral anticoagulation over antiplatelets, while intermediate-to high-mortality risk according to the PROFUND index was associated with a higher likelihood of using antiplatelet therapy instead of oral anticoagulation. Longer disease duration and institutionalization were identified as determinants of VKA use over DOACs. Female gender, higher education, and having suffered a stroke determined a preferential use of DOACs. Conclusions This real-world study showed that most elderly NVAF patients received oral anticoagulation, mainly VKAs, while DOACs remained underused. Antiplatelets were still offered to a proportion of patients. Longer duration of NVAF and institutionalization were identified as determinants of VKA use over DOACs. A poor prognosis according to the PROFUND index was identified as a factor preventing the use of oral anticoagulation.
Àrees temàtiques: Saúde coletiva Psicología Medicina iii Medicina ii Medicina i Matemática / probabilidade e estatística Interdisciplinar Farmacia Educação física Ciências biológicas ii Ciências biológicas i Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: mariateresa.auguet@urv.cat
Identificador de l'autor: 0000-0003-0396-6428
Data d'alta del registre: 2024-09-28
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02019-0
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Bmc Cardiovascular Disorders. 21 (1): 384-
Referència de l'ítem segons les normes APA: Maria Mostaza, Jose; Suarez, Carmen; Maria Cepeda, Jose; Manzano, Luis; Sanchez, Demetrio (2021). Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation. Bmc Cardiovascular Disorders, 21(1), 384-. DOI: 10.1186/s12872-021-02019-0
DOI de l'article: 10.1186/s12872-021-02019-0
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications